Aileron Therapeutics Inc. (NASDAQ: ALRN) stock gained by 8.33% at last close whereas the ALRN stock price declines by 1.71% in the pre-market trading session. Aileron is a chemoprotection oncology firm in clinical development with the goal of significantly changing the chemotherapy process for cancer patients.
>> 7 Top Picks for the Post-Pandemic Economy <<
ALRN stock’ Recent Significant Update
At the European Society of Medical Oncology (ESMO) Virtual Congress 2021, Aileron Therapeutics presented significant clinical data supporting ALRN-6924’s highest potential as a chemoprotective drug. The business reported the final outcome of ALRN-6924’s Phase 1b trial in patients with small cell lung cancer (SCLC) who were receiving second-line topotecan therapy. When compared to historical controls, ALRN-6924 showed ‘triple-play efficacy’ in reducing neutropenia, thrombocytopenia, and anaemia, as well as platelet and red blood cell transfusions.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Sponsored
Read More
- 3 Best Gene Therapy Stocks for long-term Investment
- Two of the Best Pharmaceutical Stocks to Watch for in 2021
Aileron also announced initial findings from ALRN-6924’s ongoing Phase 1 pharmacology study, which proved 0.3 mg/kg as the ideal dose and confirmed ALRN-6924’s novel p53 biomarker-driven mechanism of action, as well as its pharmacodynamic impacts, such as time to onset, magnitude, and duration.
ALRN-6924 is being developed by Aileron to preserve healthy cells in patients with malignancies that have p53 mutations, reducing or eliminating chemotherapy-induced adverse effects while keeping chemotherapy’s ability to destroy cancer cells. ALRN-6924, a first-in-class MDM2/MDMX dual inhibitor, is meant to stimulate p53 in normal cells, which in response upregulates p21, which in normal cells but not in p53-mutated cancer cells, arrests cell cycle.
Manuel Aivado, President and CEO of Aileron commented,
They’re excited to share the full results of ALRN-6924’s Phase 1b trial in patients with SCLC receiving topotecan, as well as preliminary findings from their current Phase 1 pharmacology investigation in healthy volunteers. Their optimism in ALRN-6924’s best-in-class potential in the burgeoning chemoprotection sector is strengthened by the data presented at ESMO. The goal with their precision medicine method is to make the first selective chemoprotective medication available to all patients with p53-mutated cancer while assuring that treatment is not interrupted. Chemoprotection during chemotherapy, they feel, should eventually be as mandatory as anaesthetic after surgery.
